Daily Piece: Potential Game Changer – Biosimilar Insulin Products

Insulin pricing and cost is at the front of everyone’s mind these days in the diabetes world. FDA is transitioning certain biologic products (i.e. insulin) which are currently regulated under the Federal Food, Drug and Cosmetic Act to be licensed as biologics under the Public Health Service Act. This is a game changer because it will biosimilar insulins to come to market for the first time. Ideally, this competition will help drive down insulin costs. Time will tell.

https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm628121.htm

This image has an empty alt attribute; its file name is image-6.jpeg

Please share your thoughts and subscribe to receive my blogs.

#change #insulin #regulation

Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.